Blogs
Comparing GLP-1 Options in 2025 — Ozempic, Wegovy, Zepbound, Mounjaro, and Beyond
Which GLP-1 medication is best for weight loss in 2025? We compare Ozempic®, Wegovy®, Zepbound®, Mounjaro®, CagriSema, Retatrutide, and more to help providers and patients navigate their options.
Read More
The Semaglutide and Tirzepatide Shortage Has Eased—Here’s What Patients and Providers Need to Know
As semaglutide and tirzepatide return to pharmacy shelves, many patients and providers are asking—what now? Here’s a breakdown of current options, emerging therapies, and best practices for GLP-1 treatment.
Read More
Enhancing GLP-1 Therapy Outcomes: The Role of Amylin Analogues and SLM+
Enhance GLP-1 therapy with amylin analogues like pramlintide and SLM+. Discover how to maximize weight loss results with STAAR LABS’ research insights.
Read More
The Future of Weight Loss: Emerging GLP-1 Therapies and STAAR LABS’ Amylin Research
Explore emerging GLP-1 therapies like amylin analogues and Retatrutide. Learn about STAAR LABS’ research on pramlintide and SLM+ for weight loss in 2025.
Read More
Why Liraglutide and Dulaglutide Aren’t Enough: The Search for a Better GLP-1 Solution
Liraglutide and dulaglutide fall short for weight loss compared to tirzepatide. Learn why and explore better GLP-1 solutions in this educational post.
Read More
Tirzepatide and Semaglutide Shortages Resolved: What’s Next for Patients and Providers?
Tirzepatide shortage resolved in 2024, semaglutide in 2025. Explore GLP-1 therapy options, pros, and cons for patients and providers in this educational post.
Read More